Goldman Sachs
TELO icon

Goldman Sachs’s Telomir Pharmaceuticals TELO Stock Holding History

Goldman Sachs’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,411
Closed -$13.5K – 7059
2026
Q1 		$13.5K Buy
+10,411
New +$13.3K ﹤0.01% 6374
2025
Q4 		– Sell
-22,636
Closed -$31.5K – 6876
2025
Q3 		$31.5K Sell
22,636
-137,958
-86% -$208K ﹤0.01% 6213
2025
Q2 		$201K Buy
160,594
+128,312
+397% +$297K ﹤0.01% 5664
2025
Q1 		$104K Sell
32,282
-18,248
-36% -$79.8K ﹤0.01% 5780
2024
Q4 		$208K Buy
+50,530
New +$238K ﹤0.01% 5630

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Goldman Sachs's TELO Position: Q2 2026 in Review

Goldman Sachs sold out of Telomir Pharmaceuticals (TELO) in Q2 2026, closing a stake of 10,411 shares — an estimated $13.5K sold.

Goldman Sachs first reported a position in TELO in Q4 2024 and held it in 5 quarters. The position peaked at $208K in Q4 2024. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • Goldman Sachs reported no remaining Telomir Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 10,411 Telomir Pharmaceuticals shares in Q2 2026, an estimated $13.5K.
  • Goldman Sachs first reported a position in Telomir Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • Goldman Sachs's Telomir Pharmaceuticals position peaked at $208K in Q4 2024.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.